(Total Views: 588)
Posted On: 05/04/2025 8:32:53 AM
Post# of 155791
Re: KenChowder #152238
Dec. 2024, 36+/48+ & ESMO off-site meetings:
Oncology – December 2024 Update
The Company will be prioritizing oncology in 2025, as we believe this indication holds the potential for the highest value return to the Company in the form of a significant partnership and/or drug approval.
Oncology – December 2024 Update
The Company will be prioritizing oncology in 2025, as we believe this indication holds the potential for the highest value return to the Company in the form of a significant partnership and/or drug approval.
(4)
(0)
